Regulatory Aspects of Drug Labeling and Packaging in India

Background and Regulatory Philosophy

Overarching philosophy is one of consumer protection through mandated transparency. The state assumes the crucial role of a guardian, setting legally enforceable standards to ensure that every drug sold is safe, effective, and of good quality[1]. The ultimate goal is to empower both healthcare professionals and patients with the information needed for the safe and effective use of medicines. This is achieved by ensuring all labeling is truthful, not misleading, and provides all necessary information for the product's identification, safe handling, administration, and storage[2][3].

Historical Evolution of Drug Regulation in India

The journey of drug regulation in India began in the pre-independence era, catalyzed by a largely unregulated market rife with counterfeit and unsafe medicines. The 1930 Chopra Committee's findings on large-scale adulteration and misbranding were pivotal, leading to the passage of the "Drugs Act" in 1940 under the Government of India Act, 1935[4].

After independence, the Act was significantly broadened. In 1945, the Drugs and Cosmetics Rules were promulgated to provide detailed operational guidelines. That same year, the scope of the Act was expanded to include cosmetics. Subsequent amendments have continuously adapted the Act to new challenges: traditional Indian medicine systems (Ayurveda, Siddha, Unani) were brought under its ambit in 1964, and penalties for spurious drugs were severely strengthened in the 1982 and 2008 amendments. Most recently, in 2020, medical devices were formally brought under the Act's purview. Today, the framework continues to evolve, incorporating WHO standards and addressing modern areas like biosimilars and digital health[5][6].

Importance of Labeling and Packaging in Pharmaceutical Safety

Labeling and packaging are the final critical steps before a drug reaches a patient, serving several key safety functions: they are the primary means of product identification through proper and brand names, the basis for patient information about dosage, storage, and expiry dates, and the medium for legal safeguards via mandatory warnings for prescription drugs. Furthermore, features like tamper-evident packaging and unit-of-use labeling help prevent medication errors and ensure patients receive a safe, unadulterated product[7].

The Drugs and Cosmetics Act, 1940 – Overview and Objectives

The Drugs and Cosmetics Act, 1940 (D&C Act) is the principal legislation governing all drugs and cosmetics in India. Enacted by the Parliament of India, its primary objectives are to regulate the import, manufacture, distribution, and sale of drugs and cosmetics, and to ensure that these products meet prescribed standards of quality, safety, and efficacy, thereby preventing the circulation of misbranded, adulterated, or spurious products[8].

The Act is organized into several chapters. Critical among these are Chapter III, which empowers the government to regulate the import of drugs, and Chapter IV, which provides for the regulation of their manufacture, sale, and distribution. The Act is enforced by the Central Drugs Standard Control Organisation (CDSCO) at the central level and respective State Drugs Control Administrations at the state level, with advisory support from bodies like the Drugs Technical Advisory Board (DTAB)[8].

The Legal Metrology (Packaged Commodities) Rules, 2011

Overlapping with the D&C Rules, the Legal Metrology (Packaged Commodities) Rules, 2011 are administered by the Department of Consumer Affairs. These rules govern the labeling of all "pre-packaged commodities," including drugs, and aim to ensure that consumers receive all necessary information about a product's identity, quantity, origin, and price before purchase. Key mandatory declarations under Rule 6 include the name and address of the manufacturer, country of origin for imported goods, net quantity, month and year of manufacture, MRP (inclusive of all taxes), and consumer care details[9][10].

All declarations must be made on the Principal Display Panel (PDP) of the package, with specific font size requirements. The minimum height of numerals and letters varies based on the area of the PDP, promoting legibility[11].

The Consumer Protection Act, 2019

The Consumer Protection Act, 2019 (CPA) replaced the 1986 Act and introduced a more robust framework for product liability. It is particularly relevant to the pharmaceutical industry as it holds manufacturers, sellers, and service providers liable for any harm caused by defective products, which can include a drug with inadequate or misleading labeling[12].

The CPA 2019 provides a clear and expanded definition of a "consumer" and empowers the newly formed Central Consumer Protection Authority[13][14] (CCPA) to act against unfair trade practices, including false or misleading advertisements. For a drug label, non-compliance with D&C Rules could be argued as a "defect" under the CPA, opening the manufacturer to claims for compensation[15].

The Drugs (Price Control) Order, 1995

The Drugs (Price Control) Order, 1995 (DPCO, 1995) regulates the prices of pharmaceutical drugs in India. While primarily an economic regulation, it has a direct and significant impact on labeling. Para 14 and 15 of the DPCO require that every manufacturer print the Maximum Retail Price (MRP) on the label of the drug pack[16].

The DPCO further mandates that the MRP must be the retail price inclusive of all taxes, and it must be clearly displayed. The implementation of the DPCO is overseen by the National Pharmaceutical Pricing Authority (NPPA), which also fixes ceiling prices for scheduled drugs. The order prohibits manufacturers from selling the drug to a consumer at a price exceeding the printed MRP, making this a critical component of every drug package label[17][18].

Schedules Under the Drugs and Cosmetics Rules and Their Impact on Labeling

The Drugs and Cosmetics Rules, 1945, are structured into various Schedules (designated by letters of the alphabet and alpha?numerical designations such as C, C(I), F, G, H, H1, H2, J, M, P(I), R, and X), which contain specific requirements that supplement the general labeling and packaging mandates[19][20]. These Schedules categorize drugs based on their pharmacological class, risk profile, therapeutic use, and other special attributes such as potential for abuse or specific product type. For each category, the Rules prescribe detailed labeling requirements—including specific cautionary statements, distinctive markings such as colored symbols, warnings, storage conditions, permitted pack sizes, and in some cases, specialized packaging or coding requirements such as QR codes. An understanding of these Schedules is essential for achieving compliance, as the penalty for non?compliance may include product recall, license cancellation, and criminal prosecution[21].

Schedule A – Forms and Reference for License Number Formatting

Schedule A lists the “Forms” prescribed under the Rules. These are essentially the standard application forms for licenses, permits, and other regulatory documents, including applications for manufacturing licenses, import licenses, and sale licenses. However, a critical labeling implication arises from the requirement that every drug manufactured in India must bear the manufacturing license number on its label, preceded by the words “Manufacturing Licence Number” or “Mfg. Lic. No.” or “M.L.[22][23]”. The same principle applies to imported drugs, which must display the import license number in the prescribed format. This mandatory disclosure enables regulatory authorities to trace the product to the licensed manufacturer or importer, serving as a primary anti?counterfeiting tool. Additionally, the label must not refer to any import license number granted by an authority outside India. Manufacturers must therefore ensure that the license number is printed legibly and permanently on the label, using the exact terminology prescribed[24].

Schedule C & C(I) – Biological Products, Antibiotics and Parenterals

Schedules C and C(I) contain the list of biological and special products that must comply with additional standards of strength, quality, and purity. These Schedules cover products such as vaccines, sera, toxins, antitoxins, immunoglobulins, hormones, antibiotics, and products derived from living organisms, as well as preparations intended for parenteral administration. The labeling implications are significant[25][26]. For drugs falling under these Schedules, the label must clearly state the proper name of the biological product, the batch number, date of manufacture, and date of expiry. Additionally, special storage conditions (such as “Store at 2–8°C” or “Do not freeze”) must be prominently displayed, as biological products are highly sensitive to environmental conditions. The label must also include a clear statement regarding the route of administration, and for parenteral products, the volume of solution and concentration of active ingredient must be specified. These enhanced labeling requirements ensure that the product is handled and administered correctly, preserving its therapeutic integrity[27][28].

Schedule F – Biological Products (Sera, Vaccines) – Deleted and Replaced

Historically, Schedule F contained specific provisions for the manufacture, testing, and labeling of biological products such as sera and vaccines. However, the entry relating to Schedule F has been effectively deleted, with the relevant biological products now covered under Schedules C and C(I) and Part X of the Rules[29][30]. Manufacturers should therefore note that any reference to Schedule F is obsolete for compliance purposes, and the current regulatory framework requires adherence to the provisions of Schedules C, C(I), and Part X for all biological and parenteral products. The deletion reflects the rationalization of the Rules to avoid duplication and to align with international standards for biological products[31][32].

Schedule G – Drugs Requiring Medical Supervision

Schedule G contains a list of drugs that are considered dangerous to take without medical supervision due to their potential for serious adverse effects, but which are not strictly restricted to prescription?only sale[32][33]. These include hormonal medications (excluding sex hormones), antineoplastic drugs, anticonvulsants, oral hypoglycemics, antihistamines, and certain other categories that require professional guidance for safe use.

The most critical labeling requirement for Schedule G drugs is set out in Rule 97, which mandates that the container of every drug specified in Schedule G for internal use must bear the following cautionary statement[34] The statement must be conspicuously printed and surrounded by a line, within which there shall be no other words. This distinctive formatting draws immediate attention to the warning and distinguishes Schedule G drugs from ordinary over?the?counter products. Additionally, records of purchase and sale of Schedule G drugs must be maintained for two years. These labeling requirements empower patients to recognize that the medicine is not safe for indiscriminate self?medication and should be used only under proper medical guidance[35][36].

Schedule H – Prescription?Only Drugs

Schedule H is one of the most significant Schedules from a labeling perspective, as it covers a wide range of drugs that can be sold only on the prescription of a Registered Medical Practitioner (RMP). Drugs listed in Schedule H include antibiotics, psychoactive substances, cardiovascular drugs, steroids, and other potent medications that require strict medical supervision. The label of such drugs must conspicuously bear the symbol “Rx” on the left top corner of the label. Additionally, the following warning must be printed[37]:

“Schedule H drug – Warning: To be sold by retail on the prescription of a Registered Medical Practitioner only[38]”

This label functions as a legal restriction on dispensing the drug without a valid prescription. Pharmacists are required to verify the prescription before sale, and failure to adhere to this requirement can result in penalties[38][39].

Schedule H1 – Higher?Risk Prescription Drugs

Schedule H1 was introduced to bring higher?risk prescription drugs under stricter control, addressing concerns regarding misuse and addiction. Schedule H1 drugs include certain narcotic analgesics, sedatives, hypnotics, tranquillisers, antidepressants, steroids, and cancer drugs that have a high potential for abuse or serious adverse effects. The labeling requirements for Schedule H1 drugs are more stringent than those for Schedule H.

Every drug specified in Schedule H1 must be labeled with the symbol “Rx” in red colour, conspicuously displayed on the left top corner of the label. In addition, the label must bear the following two warnings in legible black?coloured ink inside a red rectangular box:

“Schedule H1 drug – Warning: It is dangerous to take this preparation except in accordance with the medical advice” and “Not to be sold by retail without the prescription of a Registered Medical Practitione[28]r”

The use of a red border and a red “Rx” symbol distinguishes Schedule H1 drugs from ordinary prescription drugs and serves as a visual alert to pharmacists and patients regarding the elevated risk. Furthermore, supplies of Schedule H1 drugs must be recorded in a separate register at the time of supply, including the name and address of the prescriber, the name and address of the patient, and the quantity supplied. These enhanced controls help curb drug abuse and promote rational prescribing.

Schedule H2 – Top 300 Drug Brands (QR Code / Barcode Mandatory)

Schedule H2 is a recent addition to the Rules and represents a significant step towards digital authentication of pharmaceutical products. Schedule H2 lists the top 300 drug formulation brands in India by market volume, and it mandates that manufacturers of these products print or affix a barcode or Quick Response (QR) code on the primary packaging label of each drug. In cases where space on the primary package is inadequate, the code may be placed on the secondary package label[24].

This requirement, which came into force on August 1, 2023, applies to all drugs listed in Schedule H2, and the information embedded in the QR code must be readable with a software application to facilitate authentication. The minimum data to be encoded includes:

• Unique product identification code
• Proper name and generic name of the drug
• Brand name
• Name and address of the manufacturer
• Batch number
• Date of manufacturing
• Date of expiry
• Manufacturing license number

The QR code requirement helps combat counterfeiting and facilitates product traceability throughout the supply chain. Additionally, in response to the government’s expansion of the QR code mandate, effective March 1, 2026, Schedule H2 drugs will also require excipient disclosure. This means that manufacturers must declare on the label all excipients used in the product, along with their quantities or percentages, enhancing transparency for patients who may have allergies or sensitivities to specific excipients[26].

Schedule J – Prohibited Disease Claims

Schedule J contains a list of diseases and ailments for which no drug may claim to prevent or cure. The list includes serious conditions such as cancer, diabetes, AIDS, paralysis, baldness, heart block, and several other incurable or chronic diseases. Under Rule 106 of the Drugs and Cosmetics Rules, a drug cannot make any claim on its label or in any advertisement that it treats or prevents any of the diseases listed in Schedule J. The prohibitions extend to any disease or condition “by whatever name described”.

The labeling implication is straightforward but crucial: drug manufacturers must ensure that their product labels do not contain any explicit or implied claim regarding the cure or prevention of any disease listed in Schedule J. This includes the use of brand names, packaging illustrations, or promotional literature that could be interpreted as making such a claim. Regulatory authorities strictly enforce this provision, and violations can lead to seizure of products, penalties, and legal action. The prohibition protects consumers from misleading claims and reinforces the need for scientifically validated therapeutic indications[29][30].

Schedule M – Good Manufacturing Practices (GMP) Requirements

Schedule M is the cornerstone of Good Manufacturing Practices (GMP) for pharmaceutical products in India. It details the requirements for premises, plant, equipment, documentation, quality control, and personnel to ensure that drugs are consistently produced and controlled according to quality standards. While Schedule M primarily governs manufacturing processes, it has direct implications for labeling.

Under Schedule M, labeling operations must be performed in a manner that prevents mix?ups and ensures accuracy. The revised Schedule M, aligned with WHO GMP standards and effective from December 28, 2023, introduced a pharmaceutical quality system (PQS) and quality risk management (QRM). Specifically, labels must be clear, unambiguous, and in the company’s format. The finished product must bear labeling that includes[31]:

• Product name
• List of active ingredients
• Batch number
• Date of manufacturing
• Date of expiry
• Storage conditions
• Manufacturing license number

Additionally, labeling materials must be stored securely and issued only as per documented instructions. The Schedule also mandates that labeling artwork be approved by the quality control department before use and that printed labels be reconciled after each batch. The updated GMP requirements, to be fully implemented by 2025, also require computerized systems for storage and documentation, which would apply to labeling records and artwork management. Compliance with Schedule M is mandatory for obtaining and retaining a manufacturing license.

Schedule P(I) – Pack Sizes of Drugs

Schedule P(I) (often referred to as Schedule P?1) prescribes the permitted retail pack sizes for various drug formulations in India. The Schedule lists drugs by name, dosage form, and the specific pack sizes that may be marketed, and no other pack size is permitted unless specifically exempted[32].

In addition to the specific entries in Schedule P(I), Rule 105 of the Drugs Rules provides general guidance for drugs not covered by the Schedule:

• For tablets and capsules: Where the number of tablets or capsules is less than 10, packing shall be in integral numbers. For numbers above 10, the pack size must contain multiples of 5.
• For liquid oral preparations: Permitted pack sizes are 30 ml (paediatric only), 60 ml, 100 ml, 200 ml, and 450 ml.
• For paediatric oral drops: Permitted sizes are 5 ml, 10 ml, and 15 ml.
• For eye, ear, and nasal drops: Permitted sizes are 3 ml, 5 ml, and 10 ml.
• For eye ointment: Permitted sizes are 3 g, 5 g, and 10 g.

The labeling implication is that the pack size stated on the label must exactly correspond to the sizes prescribed in Schedule P(I) or Rule 105, as applicable. The label must clearly indicate the net quantity in metric units (milliliters, grams, or number of units). Certain preparations are exempt from these pack size provisions, including imported formulations in finished form, veterinary preparations, export products, physician’s samples, and large volume intravenous fluids. Recent amendments in 2024 removed certain drugs, such as Glyceryl Trinitrate and Isosorbide Dinitrate, from Schedule P(I)[33][34].

Schedule R – Condoms, Copper?T, Contraceptives

Schedule R contains the standards and labeling requirements for condoms made of natural rubber latex intended for single use, as well as other mechanical contraceptives such as Copper?T (intrauterine devices), diaphragms, and tubular rings. The labeling requirements for products under Schedule R are precise[35][36]:

• The label must clearly state the date of manufacture and the date up to which the contraceptive is expected to retain its properties (expiry date).
• The batch number must be clearly marked.
• The name and address of the manufacturer must be prominently displayed.
• Instructions for use, including disposal instructions after single use, must be provided.
• The packaging (wallet and carton) must conform to the prescribed specifications.

Products under Schedule R are also required to conform to the specifications laid down from time to time by the Bureau of Indian Standards, ensuring quality and safety. Central Drugs Testing Laboratories in Mumbai and Chennai are responsible for testing these products against the prescribed standards. Proper labeling of these products is essential not only for regulatory compliance but also for ensuring correct use, which has significant public health implications for family planning programs[37][38].

Schedule X – Narcotic and Psychotropic Substances

Schedule X lists narcotic and psychotropic substances that are subject to the strictest controls under the Drugs and Cosmetics Rules and also under the Narcotic Drugs and Psychotropic Substances Act, 1985. These drugs have a high potential for abuse and addiction and are subject to stringent dispensing and record?keeping requirements.

The labeling requirements for Schedule X drugs are the most stringent:

• The label must bear the symbol “NRx” in red colour, conspicuously displayed on the left top corner of the label[39][40].
• The following warning must be printed in legible black?coloured font size within a completely red rectangular box: “Schedule X drug – Warning: To be sold by retail on the prescription of a Registered Medical Practitioner only”.
• After dispensing, the pharmacist must stamp and retain the prescription for a period of two years.[41][42]

The distinctive red “NRx” symbol immediately alerts the pharmacist and the patient to the highly regulated nature of the product. Additionally, sales and purchases of Schedule X drugs must be meticulously recorded, and any loss or theft must be reported to the authorities. These rigorous requirements are designed to prevent diversion of narcotic drugs for illicit use[43][44][45].

CONCLUSION

The various Schedules under the Drugs and Cosmetics Rules, 1945, create a tiered and nuanced regulatory framework for drug labeling in India. Each Schedule imposes distinct labeling obligations that reflect the safety profile, therapeutic use, and risk characteristics of the drug in question. Whether it is the simple caution statement for Schedule G drugs, the red “Rx” for Schedule H drugs, the red?bordered double warnings for Schedule H1 drugs, the digital QR code requirement for Schedule H2 drugs, the prohibitions on disease claims in Schedule J, the manufacturing controls under Schedule M, the pack size restrictions in Schedule P(I), the specialized labeling for contraceptives in Schedule R, or the red “NRx” symbol for Schedule X narcotics, each requirement serves a specific patient safety purpose. Manufacturers, importers, and distributors must meticulously identify the applicable Schedules for each of their products and ensure that labels comply with all relevant provisions. Regular audits and continuous monitoring of regulatory amendments are essential to maintaining compliance and protecting public health.

REFERENCES

1. Drugs and Cosmetics Act, 1940 (Act No. 23 of 1940). [Online]. Available: https://www.commonlii.org/in/legis/cen/num_act/daca1940198/.
2. Drugs and Cosmetics Act, 1940: Chapter IV. [Online]. Available: https://sooperkanoon.com/act/createfile/fileid:134/id:4597/tp:pd#1#1.
3. Drugs and Cosmetics (Amendment) Act, 2008 (Act No. 13 of 2008). [Online]. Available: https://sooperkanoon.com/act/createfile/fileid:134/id:4597/tp:pd#1#1.
4. The Drugs and Cosmetics Rules, 1945 (General & Core Provisions)
5. Drugs and Cosmetics Rules, 1945: Rule 96 (General labeling requirements). [Online]. Available: https://vaayath.com/labelling-provisions-of-drugs-in-india/.
6. Drugs and Cosmetics Rules, 1945: Rule 97 (Labelling of medicines). [Online]. Available: https://indiankanoon.org/doc/81088286/.
7. Drugs and Cosmetics Rules, 1945: Rule 97 – Requirements for Schedule H1 Drugs. [Online]. Available: https://indiankanoon.org/doc/81088286/.
8. Drugs and Cosmetics Rules, 1945: Rule 97 – Requirements for Schedule X Drugs. [Online]. Available: https://indiankanoon.org/doc/81088286/.
9. Drugs and Cosmetics Rules, 1945: Rule 97 – Requirements for Schedule G Drugs. [Online]. Available: https://indiankanoon.org/doc/81088286/.
10. Drugs and Cosmetics Rules, 1945: Rule 105 (Pack sizes of drugs not covered by Schedule P-1). [Online]. Available: https://lextechsuite.com/Drugs-and-Cosmetics-Rules-1945-105-1-Packing-of-drugs.
11. Drugs and Cosmetics Rules, 1945: Rule 106 (Prohibition of claims of cure for diseases in Schedule J). [Online]. Available: https://pharmaguddu.com/drugs-cosmetics-rules-schedule/.
12. Critical Schedules (C, C(I), G, H, H1, H2, J, M, P(I), R, X)
13. Drugs and Cosmetics Rules, 1945: Schedule C and C(I) – Biological Products, Antibiotics & Parenterals. [Online]. Available: https://pharmaguddu.com/drugs-cosmetics-rules-schedule/.
14. Drugs and Cosmetics Rules, 1945: Schedule G – Drugs requiring medical supervision. [Online]. Available: https://pharmaguddu.com/drugs-cosmetics-rules-schedule/.
15. Drugs and Cosmetics Rules, 1945: Schedule H – Prescription Only Drugs. [Online]. Available: https://pharmaguddu.com/drugs-cosmetics-rules-schedule/.
16. Drugs and Cosmetics Rules, 1945: Schedule H1 – Higher Risk Prescription Drugs. [Online]. Available: https://indiankanoon.org/doc/81088286/.
17. Drugs and Cosmetics Rules, 1945: Schedule H2 – Top 300 Drug Brands (QR Code Mandate). [Online]. Available: https://health.economictimes.indiatimes.com/news/pharma/qr-codes-on-schedule-h2-drugs-will-it-address-the-issues-of-counterfeiting/97947918.
18. Drugs and Cosmetics Rules, 1945: Schedule J – Prohibited disease claims. [Online]. Available: https://pharmaguddu.com/drugs-cosmetics-rules-schedule/.
19. Drugs and Cosmetics Rules, 1945: Schedule M – Good Manufacturing Practices (Revised 2023). [Online]. Available: https://www.newindianexpress.com/nation/2025/Nov/08/dcgi-orders-states-to-enforce-revised-schedule-m-norms-launch-inspections-of-drug-units.
20. Drugs and Cosmetics Rules, 1945: Schedule P(I) – Pack Sizes of Drugs. [Online]. Available: https://lextechsuite.com/Drugs-and-Cosmetics-Rules-1945-105-1-Packing-of-drugs.
21. Drugs and Cosmetics Rules, 1945: Schedule P(I) – Removal of Glyceryl Trinitrate and Isosorbide Dinitrate (MoHFW, 2024). [Online]. Available: https://medicaldialogues.in/news/industry/regulations/glyceryl-trinitrate-isosorbide-dinitrate-removed-from-schedule-p1-mohfw-125495.
22. Drugs and Cosmetics Rules, 1945: Schedule R – Condoms, Copper-T, Contraceptives. [Online]. Available: https://www.pharmdinfo.com/community-pharmacist-forum-f255/what-is-schedule-q-and-r-t3265.html?view=print.
23. Drugs and Cosmetics Rules, 1945: Schedule X – Narcotic and Psychotropic Substances. [Online]. Available: https://indiankanoon.org/doc/81088286/.
24. Specialized Parts of the Drugs Rules (Part IX, IX-A, X, XV, XVII)
25. Drugs and Cosmetics Rules, 1945: Part IX – Labeling and Packing of Drugs (Other than Homoeopathic). [Online]. Available: https://vaayath.com/labelling-provisions-of-drugs-in-india/.
26. Drugs and Cosmetics Rules, 1945: Part IX-A (Rule 106A) – Manner of labelling of Homoeopathic medicines. [Online]. Available: https://lextechsuite.com/Drugs-and-Cosmetics-Rules-1945-106A-Manner-of-labelling-of-Homoeopathic-medicines.
27. Drugs and Cosmetics Rules, 1945: Part IX-A (Rule 106C) – Prohibition on Proprietary Name for Single Ingredient Homoeopathic Medicine. [Online]. Available: https://lextechsuite.com/Drugs-and-Cosmetics-Rules-1945-106A-Manner-of-labelling-of-Homoeopathic-medicines.
28. Drugs and Cosmetics Rules, 1945: Part X (Rule 109) – Special provisions for biological products. [Online]. Available: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/drug_rules/Drugs%20Rules1945n.pdf#109#16.
29. Drugs and Cosmetics Rules, 1945: Part XV – Labelling, Packing and Standards of Cosmetics. [Online]. Available: https://corpbiz.io/learning/packing-and-labeling-compliance-for-cosmetics-products-in-india/.
30. Drugs and Cosmetics Rules, 1945: Part XVII (Rule 161) – Labelling of Ayurvedic, Siddha and Unani Drugs. [Online]. Available: https://indiankanoon.org/doc/193099376/.
31. . Labeling of Imported Drugs (Rule 104A & CDSCO Clarifications)
32. Drugs and Cosmetics Rules, 1945: Rule 104A – Prohibition against altering inscriptions on containers. [Online]. Available: https://webiis08.mondaq.com/india/healthcare/1631540/.
33. CDSCO Office Memorandum (September 20, 2023) – Initial guidance on over-printing for imported drugs. [Online]. Available: https://webiis08.mondaq.com/india/healthcare/1631540/.
34. CDSCO Office Memorandum (May 26, 2025) – Clarification on comprehensive permission for imported drugs. [Online]. Available: https://lexplosion.in/cdsco-issues-clarification-regarding-comprehensive-permission-for-overprinting-stickering-stamping-of-imported-drugs-under-rule-104a-of-the-drugs-and-cosmetics-rules-1945/
35. CDSCO Clarification: Labelling/Over-printing strictly allowed only for imported drugs (May 2025). [Online]. Available: https://webiis08.mondaq.com/india/healthcare/1631540/.
36. Legal Metrology (Packaged Commodities) Rules, 2011 – Exemption for drugs. [Online]. Available: https://sansad.in/getFile/loksabhaquestions/annex/11/AU6042.pdf?source=pqals#1#1.
37. Consumer Protection Act, 2019: Sections 82-87 – Product Liability for Defective Labels. [Online]. Available: https://www.barandbench.com/columns/product-liability-under-the-consumer-protection-act-2019-let-the-manufacturer-seller-beware.
38. Drugs (Price Control) Order, 1995: Para 14 and 15 – MRP labeling requirements. [Online]. Available: https://advocatetanmoy.com/the-drugs-prices-control-order-1995/.
39. CDSCO: Drugs Technical Advisory Board (DTAB) – 92nd Meeting Minutes (April 24, 2025). [Online]. Available: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/92nd%20DTAB%20approved%20minutes.pdf#1#1.
40. CDSCO: Drugs Consultative Committee (DCC) – 65th Meeting Minutes (December 20, 2024). [Online]. Available: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/65dcc24.pdf#1#1.
41. National Pharmaceutical Pricing Authority (NPPA) – Functions under DPCO. [Online]. Available: https://nppa.gov.in/aboutnppa.
42. Drugs and Cosmetics Act, 1940: Section 22 – Powers of Drug Inspectors. [Online]. Available: https://www.lexology.com/library/detail.aspx?g=195e5051-272c-4d70-a281-eddcafc7f9a2.
43. Drugs and Cosmetics Act, 1940: Section 17-B – Penalties for Spurious Drugs. [Online]. Available: https://corpbiz.io/learning/penalties-under-drugs-and-cosmetics-act-1940/.
44. Drugs (2nd Amendment) Rules, 2025: Rule 96(7) – Excipient Disclosure Mandate (Effective March 1, 2026). [Online]. Available: https://pharma.economictimes.indiatimes.com/news/policy-and-regulations/india-enforces-new-drug-labeling-mandate-for-excipients-quality-disclosure/123449160.
45. CDSCO Drug Recall Protocol – Immediate recall for Not of Standard Quality drugs. [Online]. Available: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2117207&reg=3&lang=1.